OCT and OCT-A Explained: What Your Retinal Specialist Sees and Why It Changes Treatment Decisions

Research-informed explainer — last updated April 12, 2026

Optical coherence tomography (OCT) is the single most important diagnostic tool in modern ophthalmology — a non-invasive scan that produces cross-sectional images of the retina at micron-level resolution, allowing your doctor to detect disease, measure damage, and track treatment response with a precision that no other technology can match. OCT angiography (OCT-A), a newer extension of the same technology, maps retinal blood vessel networks without any dye injection — revealing the capillary detail that previously required uncomfortable fluorescein procedures.

This article draws on research from five specialist physicians who were instrumental in creating and advancing this technology. Joel Schuman, MD, Co-Director of the Glaucoma Service at Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University, is co-inventor of OCT — the 1991 Science paper describing the technology (13,590 citations) is among the most cited papers in the history of ophthalmology. He also published the first in vivo retinal OCT images (894 citations), the first ophthalmic macular disease imaging study (1,266 citations), and the ultrahigh-resolution ophthalmic OCT system (951 citations). Richard Spaide, MD, Clinical Associate Professor at NYU Grossman School of Medicine and practicing at Manhattan Eye, Ear and Throat Hospital, developed enhanced depth imaging OCT for the choroid (2,173 citations), published the foundational OCT-A paper on retinal vascular layer imaging (1,585 citations), and led the first pilot study of EDI choroid imaging (1,347 citations). Srinivas Sadda, MD, A. Ray Irvine Jr. Endowed Chair at UCLA and Doheny Eye Institute, published the comprehensive OCT-A clinical review (1,650 citations). Felipe Medeiros, M.D., Vice Chair for Research at Bascom Palmer Eye Institute, published the definitive study evaluating OCT parameters for glaucoma detection (650 citations). Steven Bailey, MD, Professor of Ophthalmology at OHSU Casey Eye Institute, published the projection-resolved OCT-A anatomy study (814 citations) and quantitative OCT-A of choroidal neovascularization in AMD (726 citations).

What OCT actually does

Standard OCT works by the same physical principle as ultrasound but uses near-infrared light instead of sound waves. Low-coherence interferometry measures the delay and intensity of light reflected back from different tissue layers, constructing a cross-sectional "slice" through the retina with axial resolution of approximately 5–10 micrometers in clinical instruments.

In practice, you sit at the instrument, stare at a small fixation target, and the scan takes 1–5 seconds without touching your eye. Modern swept-source and spectral-domain OCT instruments acquire millions of A-scans per second, generating three-dimensional volumetric images of the entire macular region in seconds.

Dr. Schuman's original 1991 Science paper described the concept; his 1993 Optics Letters paper published the first in vivo human retinal images at 15-micrometer resolution. By 2001, ultrahigh-resolution OCT (the Nature Medicine paper Dr. Schuman co-authored) had reached 2–3 micrometer resolution — fine enough to distinguish individual retinal layers that correspond to distinct cell populations.

What the layers mean

A typical macular OCT scan shows 10 distinct retinal layers. The ones most relevant to clinical decision-making are:

Retinal nerve fiber layer (RNFL): The axons of ganglion cells running toward the optic nerve. Thinning here is the primary marker of glaucoma damage.

Ganglion cell layer (GCL) and inner plexiform layer (IPL): The cell bodies and dendrites of retinal ganglion cells. Loss here also indicates glaucoma, particularly in the macula where these cells are densest.

Outer retina / photoreceptors: The IS/OS junction (inner segment / outer segment of photoreceptors) appears as a bright line. Disruption or absence of this line indicates photoreceptor damage from conditions such as AMD, diabetic macular edema, or inherited retinal disease.

Retinal pigment epithelium (RPE) and Bruch's membrane: The RPE line is bright and well-defined in healthy eyes. Drusen accumulate beneath this line in early AMD; RPE detachments and breaks indicate more advanced disease.

Choroid: The vascular layer beneath the RPE. Dr. Spaide's enhanced depth imaging technique (EDI-OCT) allowed reliable measurement of choroidal thickness for the first time — previously impossible because standard OCT signal intensity falls off sharply at the RPE depth. Choroidal thinning is associated with high myopia, and choroidal thickening is seen in central serous chorioretinopathy.

How OCT drives treatment decisions in specific diseases

Glaucoma: Dr. Medeiros's study of 162 patients evaluated RNFL thickness, optic nerve head, and macular thickness parameters, finding that OCT had strong diagnostic accuracy for glaucoma with areas under the ROC curve of 0.84–0.88 for RNFL measurements. In clinical practice, the decision to escalate treatment — adding a second drop, recommending laser, or referring for surgery — is based on whether serial OCT shows statistically significant thinning of the RNFL over time, not just whether visual field tests are abnormal. Structural loss on OCT precedes functional loss on perimetry by approximately 5–7 years in early glaucoma.

Age-related macular degeneration: In wet AMD, OCT shows fluid accumulation — subretinal fluid, intraretinal fluid, and pigment epithelial detachments — that indicates active choroidal neovascularization. The presence and volume of these fluid compartments determine whether an anti-VEGF injection is needed at any given visit ("treat-and-extend" protocols). Dr. Sadda's consensus definitions for geographic atrophy on OCT (published 2017, 814 citations) established standardized criteria for measuring the area of RPE and photoreceptor loss in dry AMD — essential for clinical trials evaluating geographic atrophy treatments.

Diabetic macular edema: OCT measures central subfield thickness, the most important anatomic outcome in DME trials. Dr. Bressler's DRCR.net analysis established that baseline central subfield thickness predicts anatomic and visual outcomes after anti-VEGF treatment. A center-subfield thickness above 300 micrometers on OCT, combined with visual acuity loss, is the threshold that typically triggers treatment.

OCT-A: blood flow without dye injection

Fluorescein angiography — injecting a yellow dye intravenously and photographing its passage through retinal vessels — was the gold standard for vascular imaging for decades. It is still used for some indications, but it requires IV access, takes 20–30 minutes, and carries a small risk of allergic reaction.

OCT-A achieves comparable information about retinal vasculature by analyzing motion contrast across sequential OCT B-scans — blood cells moving through vessels scatter light differently from static tissue between scans, allowing computational separation of flow from structure. Dr. Spaide's 2014 JAMA Ophthalmology paper demonstrated that OCT-A could image all four retinal vascular layers (superficial capillary plexus, deep capillary plexus, radial peripapillary capillaries, and choriocapillaris) with detail that conventional fluorescein angiography could not achieve for the deep networks.

Dr. Sadda's comprehensive OCT-A review (1,650 citations) detailed clinical applications across AMD, diabetic retinopathy, glaucoma, and retinal vein occlusion. Dr. Bailey's projection-resolved OCT-A technique, published in Scientific Reports, corrected a major artifact problem — projection of superficial vessel patterns onto deeper layers — that had limited the accuracy of earlier OCT-A instruments. His quantitative OCT-A of choroidal neovascularization published in Ophthalmology demonstrated that lesion flow area measured by OCT-A correlates with treatment response to anti-VEGF therapy, opening the possibility of using OCT-A to guide injection intervals.

What the report in your hands means

Most OCT printouts include a thickness map of the central macula (a color-coded grid where red/orange is thick and blue/black is thin), a cross-sectional B-scan image, and for glaucoma scans, a peripapillary RNFL thickness plot compared against an age-matched normative database with green/yellow/red sectors.

Key numbers to ask about:

• Central subfield thickness (normal approximately 250–280 micrometers in adults): Above this in DME signals edema.
• Average RNFL thickness (normal approximately 95–100 micrometers around the optic nerve): Below the fifth percentile for age is flagged as outside normal limits.
• GCL-IPL thickness in glaucoma: Focal loss in sectors corresponding to visual field defects confirms structural-functional correlation.

Questions to ask your doctor

• What specific findings on my OCT scan are you using to make my treatment decision today?
• Has my RNFL thickness or macular thickness changed since my last visit, and by how much?
• Is there any fluid visible on my OCT — subretinal, intraretinal, or beneath the RPE?
• Would OCT angiography add useful information for managing my condition?
• What OCT findings would prompt you to change my treatment or escalate the dose or frequency?
• How often should I have OCT scans given my current disease stage?

The bottom line

OCT transformed ophthalmology from a field that relied primarily on subjective visual acuity and dilated fundus examination to one driven by quantitative structural measurements that detect and track disease objectively. For patients with glaucoma, AMD, or diabetic retinopathy, your OCT report is not just a picture — it is the primary data source guiding every injection, laser, and surgical decision your retinal specialist makes. Understanding what the layers represent, and asking about specific measurements at each visit, puts you in a much stronger position to participate in decisions about your own care.